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1. Introduction  
The application of quantum electronic devices like lasers and high speed MRI provide the 
potential for less invasive detection techniques and drastically improved treatment of cancer 
(Upile et al., 2011). Lasers employ the principle of stimulated photon emission to produce 
light that markedly differs in quality, depending on the wavelength of the radiation in 
ultraviolet (UV), infrared (IR) or visible regions of the spectrum (Joffee et al., 1989). In this 
context, laser fiber optics have been used for minimally invasive access and treatment of 
inoperable cerebral and head and neck neoplasms as well as tumors in other organs and 
systems (Feyh et al., 1996; Jager et al., 1996; Vogl et al., 2002a; Vogl et al., 2002b).  
For the past 50 years, several laser technologies have been employed in surgical oncology, 
including CO2 laser for cutting and coagulating and laser-induced thermal therapy  
(LITT) for thermal ablation of cancer. Photodynamic therapy (PDT) is an approach which 
has a wide range of application from acne to wrinkles, bactericidal cleansing, cancer 
treatment, etc (D'Cruz et al., 2004). In PDT, the absorption of photons by organic 
compounds can excite orbital electrons and increase kinetic energy levels leading to 
chemical reactions, but also may include light emission as fluorescence or transfer energy 
directly to oxygen molecules forming singlet and free radical species (Carmichael et al., 
1983; Paiva et al., 1996). 
Anthracyline derivatives, such as adriamycin and daunomycin, are the most common 
anticancer agents that interact with light to elicit fluorescence, membrane photo labeling, 
laser activation and killing of tumor cells (Andreoni et al., 1991; Nahabedian et al., 1988; 
Saxton et al., 1996). Studies with these anticancer agents include reports of excited states of 
these drugs and further generation of radical oxygen species which appear to be wavelength 
dependent, from 313 to 498nm (Paiva et al., 1996). Some reports have shown that yeast cells 
were sensitized and killed by adriamycin after irradiation at 365nm, a wavelength that 
presented no effect in the absence of the drug. Also, cytotoxicity of several anthracycline 
derivatives are significantly enhanced by continuous wave green light of argon (514nm) or 
KTP (532nm) laser illumination of different types of cancer, both in vitro (Li and Chignell, 
1987; Paiva et al., 1996) and in vivo.(Nahabedian et al., 1988; Peavy et al., 1992; Soudant et al., 
1992; Paiva et al., 1995).  
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Minton and Ketcham (1965) first described enhanced potentiation of the oncolytic capability 
of a pulsed ruby laser when combined with cyclophosphamide in a melanoma tumor model 
in 1965. Although lasers were initially very cumbersome in the operating room, these 
authors visualized the potential benefits of combined drug and laser tumor ablation. 
Carmichael et al. (1983) and Li and Chignelli (1987) raised the possibility of using 
chemotherapeutic drugs to photosensitize tumors since many are chromophoric and absorb 
light at specific wavelengths of the visible spectrum leading to energy transfer and oxygen 
species which cause photo-oxidation. Based on such concept, several clinical studies 
combining chemotherapy with laser therapy were developed in the mid-1990s (Lueder and 
Goyal, 1996; Murphree et al., 1996). 
Previous studies with anthracyclines such as adriamycin and daunomycin have shown 
that tumor cell peroxidation and membrane photo labeling occur immediately after drug 
uptake (Myers). Both drugs cause oxidative damage to cardiac tissue even in the absence 
of light. However, spin label experiments have been reported that show light activation of 
these drugs induces chemical bonding to many different cell membrane proteins (Li and 
Chignell, 1987). Anthracyclines initially bind to tumor cell membranes before transport in 
the nucleus and are considered to be poor type-II photosensitizers, which do not generate 
significant amounts of singlet oxygen (Andreoni et al., 1993). Nevertheless, these 
chemotherapy agents are the most tested in hopes of enhancing three distinct anti-cancer 
effects when combined with visible light: photo toxicity, thermal-toxicity and 
chemotherapy per se (Saxton et al., 1995).  
Recent attempts to reduce anthracycline toxicity led to the development of a variety of 
anthrapyrazole derivatives including DUP-941 (CI-941), which possess reduced side effects 
but has been shown to retain clinical efficacy in breast cancer patients (Diwu and Lown, 
1994). An unusual property of DUP-941 is that it has an over 100-fold increased photo-
oxidation potential compared to anthracyclines as reported by Reszka et al. (1992). Ongoing 
clinical studies are being conducted to determine the impact that this alternative approach 
of combining laser and anti-cancer agents may have on the control of disease, survival and 
quality of life in cancer patients (Paiva et al., 2005b; Paiva et al., 2005c).  
In addition to the advantage of photo-activation, several of these light sensitive 
chemotherapeutic agents have been reported to exhibit enhanced toxicity in tumor cells after 
photo-thermal-activation (Chung et al., 2003; Graeber et al., 1999; Graeber et al., 1998; Paiva 
et al., 1995; Saxton et al., 1996). As a result, a potentially useful and less invasive approach 
for treatment of malignancies is to combine imaging guided interstitial laser surgery with 
conventional chemotherapy (Paiva et al., 2005b; Saxton et al., 1995). Several FDA approved 
anti-cancer drugs are highly photosensitive or heat-responsive, including anthracycline 
derivatives and cisplatin (Paiva et al., 1997; Graeber et al., 1999). This experimental 
technique broadens the concept of tumor ablation based on thermal denaturation of 
malignant cells to include anti-cancer drug activation by laser energy (Chung et al., 2000; 
Diwu and Lown, 1994; Nahabedian et al., 1988).  
A major development is already taking place in photo chemotherapy as computer-
modeled nanoproducts have proven to be ‘’intelligently-guided’’ by heat sensitization. 
Nanoshells are optically tunable core/shell nanoparticles that can be fabricated to 
strongly absorb in the near-infrared (NIR) region where light transmits deeply into tissue 
(Saxton et al., 1995). Injecting nanoshells systemically will allow enhanced photo thermal 
ablation of tumor irradiated with the Nd:YAG laser (Feyh et al., 1996; Joffee et al., 1989). 
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Tumor specificity can be increased by functionalizing the nanoshell surface with tumor-
targeting moieties. Moreover, nanoshells can also be made to strongly scatter light and 
therefore can be used in various imaging modalities such as dark-field microscopy and 
optical coherence tomography (OCT). After adjustments to the NIR absorbing nanoshells 
have been finalized, the next step will be to explore image-guided systems in combination 
with LITT, which will be the ultimate goal of photochemotherapy as a minimally invasive 
alternative therapy for cancer.  
In this article, the authors review the literature that supports combining anti-cancer drugs 
and laser for cancer therapy. These studies suggest that photo chemotherapy with currently 
approved drugs and lasers may soon become an attractive alternative for cancer treatment. 
PDT studies were not in the scope of this work, as photodynamic application in clinical 
oncology is already a well-established subspecialty in laser technology. 
2. Laser photo-thermal therapy for cancer  
The pathway towards the realization of optical solid-state lasers was gradual and slow. 
After Einstein's paper on absorption and stimulated emission of light in 1917 it took until 
1960 for the first solid state laser device to see the light. Laser systems are widely spread in 
the field of medicine (Upile et al., 2011). The applications are divided into therapeutical and 
diagnostic applications. The main field however, is therapeutical procedures. Depending on 
the indication lasers were used for removing and cutting of smooth and hard tissue or for 
coagulation. A relative new procedure is image guided laser thermal ablation of solid 
tumors. As early as 1964, Goldman and Wilson reported clinical results on the treatment of 
basal cell epithelioma using laser radiation.  
In 1964 experimental investigations on the potential of lasers to destroy malignant tumors 
began with studies by using high energy pulsed laser radiation for treatment of multiple 
intra-abdominal tumor implants in experimental animals (Minton and Ketcham, 1964). 
Richey and Dixon (1981) investigated a similar treatment of gastric polyps by endoscopic 
application of lasers, a similar technique used by Sasako et al. (1982) for treating gastric 
cancers with the Nd:YAG laser. Hofstetter and Frank (1979) previously reported the 
successful use of laser endoscopy for clinical treatment of bladder tumors. Shapshay and 
Strong (1982), Brunetaud et al. (1981), and Carpenter et al. (1977) presented in separated 
publications, that successful management of tracheal lesions could be obtained using the 
Nd:YAG laser. Fleischer et al. (1982) reported tumor palliation in a series of 14 patients with 
end stage carcinoma of the esophagus treated with the Nd: Y AG laser.  
The Nd:YAG laser emits luminous energy in the near infrared portion of the visible 
spectrum at 1064nm and is poorly absorbed by hemoglobin, melanin and water, which leads 
to scattering of the laser beam with deep penetration into tissues (Feyh et al., 1996; Joffee et 
al., 1989; Mueller-Lisse et al., 1998; Sturesson and Andersson-Engels, 1996). Transmitting 
laser energy directly through a fiberoptic cables allows the surgeon to deliver more effective 
localized treatment, minimizing undesired tissue damage to adjacent structures, which is 
the main advantage of this adjuvant therapy for malignancies (Castro et al., 1994; Feyh et al., 
1996; Joffee et al., 1989; Paiva et al., 1998a). The Nd:YAG laser is widely used in endoscopic 
and open surgery due to its photo thermal ability to coagulate, cut, vaporize and ablate 
tissue (Castro et al., 1994; Joffee et al., 1989; Paiva et al., 1998a). Thus, the Nd:YAG is a 
unique versatile tool for localized thermal ablation of tumors.  
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The minimally invasive methods for tumor ablation currently available are using thermal 
probes, infrared thermography, and histological studies, which are reliable but have limited 
clinical usefulness (Stafford et al., 2010). Since the mid-1970s, interstitial placement of laser 
fiber optics has been applied successfully in large subcutaneous metastasis. In 1985, 
Svaasand developed some preliminary optical dosimetry for interstitial phototherapy of 
malignant tumors. About the same time Matthewson et al. (1987) investigated interstitial use 
of the Nd:YAG laser (1-2W) for hepatic hyperthermia to produce areas of thermal necrosis 
up to 16mm in the normal rat liver, and to eradicate induced rat colon tumors and 
implanted fibrosarcomas. Hashimoto et al. (1986) applied 5-15 W of Nd: YAG laser power 
with a modified diffuser fiber tip to treat liver tumors with evidence of reduction of tumor 
size. Godlewski et al. (1988) used high Nd: YAG powers (100 W), with one second duration 
to produce areas of vaporization and necrosis of 16-22 mm in porcine liver at great speed. 
However, the high power density at the distal end of the fiber optics resulted in frequent tip 
damage, burning, non-uniform distribution of laser energy, and poorly reproducible tissue 
effects. In 1985, Daikuzono and Joffe introduced synthetic sapphire probes that have high 
melting points (2020-2050°C), greater tensile strength, and a uniform pattern of laser beam 
delivery from the lateral surface of the probe. These probes allowed testing of Nd:YAG 
laser-induced hyperthermia in a dog mode1, and further developed a computer-controlled 
Nd:YAG system for interstitial local hyperthermia.  
To increase the area of necrosis that could be produced and still use one laser as the energy 
source, Steger et al. (1989) used fiber optic coupling systems to increase the number of fibers 
that could be inserted. This concept, while attractive, has proved difficult to achieve in 
practice. Nevertheless, the same author introduced the term interstitial laser hyperthermia 
in cancer treatment, which later on established itself as laser-induced thermal therapy, or 
LITT. Gatenby et al (1987) used computerized tomography (CT)-guided laser therapy for 
treatment of resistant human tumors in ten patients with favorable results. Steger et al. 
(1992) used ultrasound imaging to monitor the percutaneous interstitial Nd:YAG laser 
treatment of ten patients with liver tumors and found ultrasound imaging to be a sensitive 
monitoring technique of thermal necrosis.  
Computed tomography scanning demonstrates poor sensitivity to early tissue changes after 
laser exposure because of low soft-tissue contrast resolution. Using image-guided systems 
as CT, and ultrasound. Castro et al. (1994), at the University of California, in Los Angeles 
(UCLA) , made significant contributions to define Nd:YAG laser doses that could be safely 
translated into effective clinical application. Blackwell et al. (1993) first reported results of a 
pilot study testing interstitial laser ablation of neck tumors guided by ultrasound. The 
method later evolved into minimally invasive MRI-guided treatments as described by 
Pushek et al. (1995). Sinha et al. (1997) established temperatura monitoring system for 
thermal-ablative procedures using a software system that correlated tissue changes with 
MRI imaging.  
MRI is a non-invasive and extremely sensitive diagnostic imaging system, used to locate 
and guide biopsies of deep and difficult tumors and to access target tissues using needles 
with extremely low magnetic susceptibilities (Kahn et al., 2008; Pushek et al., 1995). MRI has 
the potential to become a three-dimensional, real-time, video imaging technique that can 
provide accurate and detailed anatomic information during laser surgery (Kahn et al., 2008; 
Vogl et al., 2002b). Important advances in clinical applications of imaging-guided laser 
ablative procedures were developed in the mid 1990s by different groups in Germany. 
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Particularly in MR-guided LITT liver tumors, Vogl et al. (1997) showed local tumor control 
between 96.3% and 98.8% after 3 months and between 95.6% and 98.8% after 6 months. No 
local recurrence was observed later than 6 months after LITT. Although the intention for 
LITT was originally palliative, its favorable survival rates compared with those obtained 
with surgical resection of liver metastases on the basis of analyses of large surgical series 
with lower complication rates, are encouraging (Vogl et al., 2002a; Vogl et al., 2002b; Vogl et 
al., 2009).  
The recent development of software programs for mathematical models of imaging-guided 
LITT should lead to more effective tumor palliation with laser therapy as an alternative to 
surgery (Mohammed and Verhey, 2005). In sum, image-guided ablation of tumors is 
assuming an increasingly important role in many oncology services as a minimally invasive 
alternative to conventional surgical interventions for patients who are not good candidates 
for surgery. LITT is now a multi-specialty procedure used for treatment of inoperable 
tumors of the brain, head and neck, breast, liver, prostate and colon, as a minimally invasive 
and low cost cancer therapy (Castro et al., 1994; Chapman, 1998; Mueller-Lisse et al., 1998; 
Paiva et al., 1998a; Schulze et al. 2002; Vogl et al., 1997; Vogl et al., 2002a; Vogl et al., 2002b; 
Mack et al., 2004; Marga et al., 2011). Further improvement will be possible by combining 
LITT with novel systemic therapy such as targeting agents, gene therapy, or nano-designed 
thermo-sensitive drugs (Kanekal et al., 2009). 
3. Photo-chemical and photo-thermal activation of anti-cancer drugs 
Tissue interactions with laser irradiation are typically classified as photochemical, 
photomechanical, and photo thermal (Feyh et al., 1996; Joffee et al., 1989). Photochemical 
effects depend on the absorption of light to initiate chemical species in photodynamic 
therapy (PDT). It is associated with low fluency rates that do not produce a significant 
temperature increase in the treated tissue, but do not interact with a natural or exogenous 
photosensitizer to produce the desired reaction. Although we will discuss photochemical 
effects of laser at length, PDT is not in the scope of this chapter for simplicity. 
Photomechanical responses occur during applications of extremely high fluency rates 
(greater than 108 W/cm2 and short laser pulses 10-6 sec. or less), which produces shockwaves 
and plasmas. Such effects occur, for example, when a laser operates in a Q-switch mode.  
Photo chemotherapy with lasers is an alternative therapy which consists of using a 
monochromatic light delivered via external irradiation or via interstitial fiber optics to 
enhance the ``killing`` threshold in tumors containing light and/or heat -sensitive anti-
cancer agents (Saxton et al., 1995). The development of photoactivatable pro-drugs of 
platinum-based antitumor agents is aimed at increasing the selectivity and thereby lowering 
toxicity of this important class of antitumor drugs (Bednarski, 2007; Farrer et al., 2010). 
Hence, laser chemotherapy explores two distinct mechanism of antitumor action: ( 1- ) direct 
toxic effect, and ( 2- ) additional photochemical and/or photo thermal toxicity (Bednarski, 
2007; Crescenzi et al., 2004; Eshraghi et al., 1997; Mackay et al., 2007).  
These drugs may be injected intravenously at concentrations lower than normal 
chemotherapeutic levels, or at higher intratumor doses reducing systemic toxicity while 
enhancing local tumoricidal effects by laser photoactivation in situ (Nahabedian et al., 1988; 
Paiva et al., 1998c). Other anthracyclines have also been identified that have greater 
photosensitization potential than daunomyucin (Diwu and Lown, 1994). With all the 
supporting evidence of translational studies, photochemotherapy has been established as an 
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alternative treatment for retinoblastoma (Peterson et al., 2011). Most of these studies were 
conducted in children where there has been a few standardized clinical protocols, in 
particular for unilateral retinoblastoma (Leng et al., 2010; Mallipatna et al., 2009; Gallie et al., 
1996; Lueder and Goyal, 1996; Murphree et al., 1996; Saxton et al., 1996  
The first reports of DUP-941 as an intratumor sensitizing drug for phototherapy in a 
subcutaneous squamous cell carcinoma (SCCA) transplant model in nude mice were 
published in 1995 (Paiva et al., 1995). This experimental treatment showed intralesional 
injections at 60μg DUP-941 per gram of tumor led to stasis but no regression. LITT 
administered via fiber optics at low energy levels (continuous green light, 532nm, power 
density = 13.4 J/cm2) also resulted in tumor recurrence in over 80% of the animals. 
However, combined intratumor DUP-941 and LITT at the same dose levels of drug and laser 
energy produced tumor eradication in over 90% of treated animals with no recurrence 
detected during a 12-week follow-up period. This was the first effort in the literature to 
explore the concept of local injection of anti-cancer drug combined with laser interstitial 
therapy for cancer treatment. Additional testing in a larger group of animals in Germany by 
Graeber et al. (1998) confirmed these results, which provide strong preclinical evidence in 
support of the hypothesis that photo chemotherapy may be an alternative treatment for 
human tumors. Similar LITT studies have followed with a translational experimental model 
combining intratumor cisplatin with Nd:YAG laser for thermal ablation of recurrent and 
advanced head and neck cancer (Paiva et al., 1998b; Graeber et al., 1999).  
Despite important advances in current therapy with surgery, radiation, and chemotherapy, 
nearly one half of all head and neck cancer patients will develop persistent or recurrent 
disease (Adelstein, 1998; Argiris et al., 2010; Bonner et al., 2006; Correa and Burkey, 1999; 
Weisman and Robbins, 1998). Head and neck tumors are an excellent disease model for 
testing intratumor chemotherapy and laser because of their accessibility for surgery and 
their loco-regional biological behavior (Paiva et al., 1997). The laser energy can be delivered 
via interstitial fiber optics using drugs activated by photo-chemical and  photo-thermal 
energy as a potential less invasive treatment alternative for cancer (Paiva et al., 2005c; Paiva 
et al., 1997; Graeber et al., 1999). Moreover, there has been no generally accepted standard of 
care for recurrent head and neck cancer (Goodwin et al., 2000; D'Cruz et al., 2004; Arnold et 
al., 2004; Fury et al., 2011). At UCLA, Phase I and II clinical trials have been conducted using 
LITT in a stepwise fashion to palliate patients with advanced and recurrent head and neck 
tumors as an alternative to more radical and at times disabling surgery (Castro et al., 1994; 
Paiva et al., 1998a; Paiva et al.; 2002a).  
4. The rationale for cisplatin and laser thermal-therapy for cancer 
Platinum-based compounds were first synthesized in the nineteenth century but their 
clinical use against cancer did not start until the 1970s (Higby et al., 1974). Cisplatin [(SP-4-
2)-diamminedichloroplatinum] was the first of the platinum drugs to be approved for the 
treatment of both ovarian and testicular cancer in 1978 and is also administered for many 
other types of solid tumors. Second-generation platinum derivative carboplatin [cis-
diammine (cyclobutane-1,1-dicarboxylate-O,O_)platinum(II)] differs from cisplatin in the 
substitution of two chlorides by a 1,1-cyclobutane dicarboxylate group. Its efficacy in the 
treatment of the above malignancies is equal to that of cisplatin, and its toxicity profile is 
more favorable and was approved in March 1989 for treatment of ovarian cancer (Ozols et 
al., 2003). Thus, carboplatin has often been used in place of cisplatin (Syrigos et al., 2010; 
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Gkiozos et al., 2007). Oxaliplatin [[(1R,2R)-cyclohexane-1,2-diamine](ethanedioate-
O,O_)platinum(II)] is a third generation platinum compound approved in 2002 
(Charalabopoulos et al., 2002). Oxaliplatin is widely used for the treatment of metastatic 
colorectal cancer and a variety of other malignancies, such as breast cancer, melanoma, non-
Hodgkin lymphoma, and head and neck cancer (Makrilia et al., 2010). The other names for 
cisplatin are DDP, cisplatinum, and cis-diamminedichloridoplatinum(II), or CDDP. 
Common adverse events are myelotoxicity, nausea, vomiting, diarrhea, paresthesia, and 
dysesthesias (Makrilia et al., 2010).  
The mechanism of anticancer activity of cisplatin is by forming a platinum complex inside of 
a cell which binds to DNA and cross-links DNA. Consequently, crossed-linked DNA causes 
the cell to undergo apoptosis, or systematic cell death. Cross-linking ensues apoptosis by 
damaging the DNA so that the repair mechanisms for DNA are activated, and once the 
repair mechanisms are activated and the cells are found to not be salvageable, the death of 
those cells is triggered instead. Clearly, the use of platinum derivatives is essential in the 
fight against cancer, and currently it is the most commonly used chemotherapy drug in the 
United States (Seiwart et al., 2007). However, the toxic side effects must be attenuated to 
reap the maximum benefits, which is why other uses are devised exploring distinct 
synergistic effects when combining cisplatin with a regimen of other anti-cancer drugs, 
radiotherapy, whole body hyperthermia, and more recently biologic therapy (Amichetti et 
al., 1993; Goodwin, 2000; Bonner et al., 2006; Seiwart et al., 2007; Fury et al. 2010). 
Whole body hyperthermia has been studied clinically for nearly two decades with respect to 
cancer treatment and has been shown to enhance tumoricidal effects of irradiation as well as 
chemotherapy with adriamycin (doxorubicin) and cisplatin (Amichetti et al., 1979; Hahn, 
1979; Baba et al., 1989; Storm et al. 1989; Ohno et al., 1994; Engin, 1996; Cezamar et al., 2001; 
Arancia et al., 2001; Hahn and Shiu, 1983; Noel et al., 2003). In these studies, near maximum 
effects were observed when both modalities (i.e., hyperthermia and chemotherapeutic 
agents) were administered simultaneously (Hahn, 1979; Teicher and Herman, 1992). At 
temperature levels above 43°C, heat also appears to reverse acquired resistance to cisplatin 
(Hahn, 1979; Cezamar et al., 2001). In particular, hyperthermia enhances the activity of 
cisplatin by potentiating tumoricidal effects progressively as intra-tumor temperature is 
elevated to 43°C resulting in synergistic lethal effects for cancer cells (Ohno et al., 1994; 
Engin, 1996). Thermo-chemotherapy using systemic fever-range (40 Co) temperature for 
long durations (4-6 h) has better or equal anti-cancer efficacy compared to maximally-
tolerated systemic temperatures (41.5 Co–42 Co), and generally results in less toxicity (Bull et 
al., 2008a). 
Bull et al. (2008a) determined the maximally tolerated dose (MTD) of cisplatin administrated 
within a regimen of fever-range whole body thermal therapy to be 60mg/m2. Since 
hyperthermia has the potential to interfere with many mechanisms that cause cisplatin 
resistance, it may also be a suitable modality to interfere with acquired resistance 
(Oldenburg et al., 1994; Bull et al., 2008a). Apparently, the mechanisms responsible for 
hyperthermic cell killing and hyperthermic drug sensitization must, in part, be the same 
(Hettinga et al., 1995). Heat has been shown to cause denaturation of cellular proteins. This 
leads to an increase in protein mass of nuclei isolated from heated cells. Under several 
conditions, including thermo tolerance, a good correlation has been found between the 
extent and duration of this ``nuclear protein aggregation`` and thermal cell rilling (Hettinga 
et al., 1995). This nuclear protein aggregation may also be one of the major mechanisms 
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responsible for thermal potentiation of killing by a number of drugs, which is by hampering 
repair of drug-induced DNA damage (Hettinga et al. 1995).  
Timing of chemotherapy, with respect to potentiation by heat, and of two drugs relative to 
each other, is critical in determining antitumor efficacy, toxicity, and survival (Bull et al., 
2008b; Teischer and Herman, 1992). Significant sequence-mediated differences in antitumor 
response demonstrated that when cisplatin is administered with gemcitabine an 
optimization of the administration schedule of multidrug chemotherapy regimens may also 
prove to be important. Therefore, preclinical optimization of the timing of chemotherapy 
drugs relative to each other, and drugs relative to heat, in multi-agent thermo chemotherapy 
regimens could significantly increase tumor response while minimizing toxicity. 
Refaely et al. (2001) studied the results of thermo chemotherapy with cisplatin in stage IVa 
patients diagnosed with thymic malignancies. They found a relatively high 3-year and 5-
year survival rates of 70% and 55% for the entire study population, and 90% and 70% for the 
thymoma patients. These results are comparable, and apparently higher than that reported 
in other series (Yellin et al., 2001). While it is important to recognize that whole body 
thermal therapy can enhance some of the toxicities associated with other treatments, the 
synergy of hyperthermia with several chemotherapy agents means that lower doses can be 
used, resulting in less toxicity. Among the collateral effects that cisplatin can cause, we find 
nausea, both acute, and chronic renal toxicity as well as long-lasting neuropathy. These 
toxicities are acute and treatable (McWhinney et al., 2009). 
There are three proposed explanations for the synergism between hyperthermia and 
cisplatinum: (1) an increase level of drugs within cells; (2) significant enhancement of the 
DNA cross-linking effect of the drugs; and (3) heat-induced inhibition of DNA repair 
(Refaely et al, 2001). Evidence indicates that heat induction leads to ultrastructural changes 
in cell membranes resulting in altered cellular metabolism and increased susceptibility to 
drug toxicity (Arancia et al., 1989; Hahn and Shiu, 1983). Higher intracellular uptake of 
CDDP induced by heat also enhances cytotoxicity in proliferating cancer cells and 
stimulates protein kinase-mediated pathway to tumor apoptosis (Noel et al., 2003). 
Drug resistant human carcinoma cells also exhibit increased CDDP uptake and cytotoxicity 
in the setting of hyperthermia (Flood et al., 1999). In addition, combined CDDP and 
hyperthermia is effective in the eradication of hypoxic tumor cells which may be resistant to 
single modality treatment with either radiation or chemotherapy alone (Storm, 1989). The 
oncogenic potential of CDDP is markedly enhanced by hyperthermia compared to drug 
treatment alone (Zanke et al., 1996; Beketic-Oreskovic et al., 1997). Studies of CDDP at the 
molecular level have shown that hyperthermia induces CDDP to bind to DNA forming 
more DNA adducts, contributes to delayed tumor growth, and amplifies inter-strand 
crosslinking (Storm et al., 1989; Hettinga et al. 1996; Los et al., 1994; Los et al., 1993). 
Altogether, the exact biological mechanism of the synergistic effect of combined cisplatin 
and heat remains unclear (Bednarski et al, 2007; Los et al., 1993).  
An initial report by Nahabedian et al. (1988) on photochemotherapy using cisplatin and 
laser (wavelength 688nm) showed that laser treatment was enhancement by systemic 
chemotherapy in murine tumors, and was the first in vivo evidence of cisplatin-photo 
activation by visible light. More recently, the development of photoactivatable prodrugs of 
platinum-based antitumor agents is aimed at increasing the selectivity and thereby lowering 
toxicity of this important class of antitumor drugs (Bednarski, 2007; Crescenzi et al., 2004; 
Mackay et al., 2007; Cubo et al, 2010). Cisplatin forms mainly intrastrand cis-diguanine 
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cross-links on DNA between neighboring nucleotides, whereas photoactivated complex-1 
rapidly forms unusual trans azido/guanine, and then trans diguanine Pt(II) adducts, which 
are probably mainly intrastrand cross-links between two guanines separated by a third base. 
DNA interstrand and DNA-protein cross-links were also detected. Importantly, DNA repair 
synthesis on plasmid DNA platinated by photoactivated-1 was markedly lower than for 
cisplatin or its isomer transplatin (an inactive complex). Single-cell electrophoresis 
experiments also demonstrated that the DNA damage is different from that induced by 
cisplatin or transplatin. Cell death is not solely dependent on activation of the caspase 3 
pathway and, in contrast to cisplatin, p53 protein did not accumulate in cells after 
photosensitization of photoactivated complex-1. The trans diazido Pt(IV) complex-1 
therefore has remarkable properties and is a candidate for use in photoactivated cancer 
chemotherapy (Cubo et al., 2010). Even though there was a lack of basic science evidence 
supporting photochemotherapy with cisplatin in the beguining of the eighties, a wealth of 
clinical investigations followed testing this experimental treatment for cancer.  
5. Clinical relevance of laser and cisplatin in photo chemotherapy 
Photochemotherapy (PCT) uses Federal Drug Administration (FDA) approved 
chemotherapeutic drugs which are first injected into to tumors, thus reducing systemic 
effects. The sensitized tumor is then activated either by photo oxidation and/or by photo 
thermal levels of energies using a monochromatic laser light which is delivered via 
external and/or interstitial fiber optics to enhance the ``killing`` threshold (Saxton et al., 
1995). Head and neck cancers are accessible for surgery and have a well documented loco-
regional biological behavior. These tumors can therefore serve as an ideal model to test 
photochemotherapy, as this approach is a possible alternative for less invasive treatment 
for cancer. 
Local recurrence in head and neck cancer is thought to be caused, in many cases, by residual 
disease and/or contamination of the surgical field during resection. Using an animal tumor 
model to investigate local recurrence, Maker et al. (1995) observed that Nd:YAG contact 
laser ablation provided about 50% improvement in the control of local disease in vivo (p< 
0.05) compared to animals treated with a scalpel. Pilot studies have demonstrated that 
Nd:YAG (1064 nm) laser induced thermal therapy may also play a role in pain control and 
allow continued nutritional support for patients with advanced or recurrent head and neck 
tumors (Castro et al., 1995a; Castro et al., 1994; Jager et al., 1996) Through repeated laser 
endoscopy, the need for a nasogastric or gastrostomy tube has been avoided as well (Jager et 
al., 1996; Mitty et al., 1996). Several studies report successful relief of malignant dysphagia 
and improvement in the quality of life with endoscopic Nd:YAG laser treatment (Karlin et 
al., 1987; Mitty et al., 1996; Sawant and Moghissi, 1994).  
Although LITT procedures are safe, feasible, and can extend survival, margin recurrence is 
seen in many cases, particularly in advanced obstructing cancers of the gastrointestinal tract 
or bronchial tree (Castro et al., 1995a; Feyh et al., 1996; Joffee et al., 1989; Mueller-Lisse et al., 
1998). In order to improve local tumor recurrence after laser treatment, Firusian (1988) was 
the first to propose combining Nd:YAG therapy with systemic chemotherapy to improve the 
final outcome in the palliation of esophageal cancer. The author reported that 13 patients 
with stenotic upper gastrointestinal cancers treated by endoscopic recanalization with laser 
ablation and systemic cisplatin in combination with other anticancer drugs responded more 
favorably compared to laser alone as a palliative approach for advanced malignant disease. 
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In most of the 13 patients, combined therapy led to immediate patency of the upper 
alimentary tract and 8 months median survival in the cohort studied. In this study it was 
also found that local laser thermal effects were enhanced by systemic chemotherapy leading 
to additional ablation of malignant cells down to 7-8mm depth compared to 4mm for laser 
treatment alone. Thus, it was concluded that combined drug and laser therapy was more 
effective in preventing rapid cell proliferation at the tumor margins (Firusian, 1988). The 
author also compared different anti-cancer agents combined with LITT ablation for 
inoperable esophageal cancer and reported that cisplatin (CDDP) was more effective than 
anthracyclines or cyclophosphamide when combined with Nd:YAG laser. However, other 
studies done in children with retinoblastoma found that Adriamycin derivatives were more 
cytotoxic in tumors after laser photo-thermal activation (Andreoni et al., 1991; Gallie et al., 
1996; Lippert et al., 2004; Lueder and Goyal, 1996; Murphree et al., 1996). From a historical 
perspective, initial work on chemotherapy and lasers was reported in clinical models 
investigating combined palliative therapy for inoperable esophageal cancers. Such reports 
were produced in Germany (Semler et al., 1985), who noticed significant improvement in 
quality of life in 21 of 24 patients with advanced gastrointestinal tumors treated by systemic 
chemotherapy administered before intraluminal endoscopic Nd:YAG laser thermal ablation. 
Mache et al. (1986) also reported on the survival benefits of this alternative combined 
treatment for palliation of advanced upper gastrointestinal tumors. In a randomized clinical 
trial, Mason et al. (1996) confirmed that patients with esophageal cancer presented a 
significant reduction in need for additional laser therapy to maintain swallowing when 
adjunctive chemotherapy was given before laser treatments. Expanding the same concept, 
Vogl et al. (2009) have recently proposed a combination of chemoembolization and LITT for 
liver tumors with promising results. An additional boost for laser thermal therapy has also 
been reported, when associating systemic cycles using IL-2 human cytokines for palliation 
of metastatic renal cell carcinoma to the head and neck (Paiva et al., 2007).  
Clinical experience with this form of combined therapy for head and neck SCCA was first 
reported on eight patients with recurrent tumors who enrolled in the first study conducted 
in the United States testing systemic chemotherapy (CDDP at 80mg/M2) followed 24 hours 
later by palliative Nd:YAG laser thermal ablation (Paiva et al., 2000). Four of the 8 patients 
treated in this manner remained alive after a median follow up of 12 months. A total of 
twelve tumor sites were treated, and complete responses were seen in the following 
anatomic locations: oral cavity (n=3), oropharynx (n=1), hypopharynx (n=1), and maxillary 
sinus (n=1). The median survival for these patients was 9.5 months. The adverse effects of 
treatment included mild alopecia in a 82 year-old female, and a bout of gastrointestinal 
infection in another patient (Paiva et al., 2000). A total of 21 patients were treated on this 
study that showed minimal toxicity of the combined treatment. However, the therapeutic 
benefit could not be demonstrated because of the variability of the tumor sites in the head 
and neck that were analyzed (Paiva et al., 2005a). One of the patients treated in this series 
presented with a recurrent SCCA of the neck after having previously undergone a 
reconstructive free flap transfer (Joo et al., 2009). The patient underwent 6 concurrent 
treatment sessions using the protocol mentioned above and demonstrated an unusually 
long period of survival (i.e., over 5 years). The remarkable survival of this patient suggests 
that the combination of LITT and chemotherapy warrants further investigation as an 
alternative treatment for patients with recurrent head and neck cancer. Studies have shown 
that even more effective eradication of head and neck cancer is possible by combining LITT 
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with local, intratumor injections of CDDP (Clayman et al., 1999). Currently, cisplatin or cis-
diamminedichloroplatinum (CDDP) are the most commonly used chemotherapeutic agents 
for head and neck cancer (Argiris et al., 2010; Bonner et al., 2006; Forastiere et al., 2006). 
technology. 
6. Intratumor injections of chemotherapy and laser for effective local  
tumor control  
Initial experimental studies combining intratumor injections of cisplatin followed by local 
hyperthermia were carried out by Kitamura et al. (1992) in a melanoma model. The authors 
demonstrated that the combined treatment led to 6-fold decreased tumor growth rate of 
melanoma and improved prognosis without nephrotoxicity or the promotion of 
hematogenic metastasis. Also, intratumor administration of cisplatin led to animal weight 
gain in this study, while mice treated with systemic drug had a significant weight loss or 
absence of weight gain (Kitamura et al., 1992). 
In the mid-1990´s several studies explored local adjunct chemotherapy to eliminate marginal 
tumor regrowth and improve final outcomes after surgery and radiation These studies had a 
strong rationale based on two reports by authors Theon et al. (1994) and Begg et al. (1994), 
who proposed adjunct local chemotherapy combined with tumor resection as a more 
effective approach for cancer treatment. The local chemotherapy proposed was based on a 
therapeutic implant of cisplatin in a gel vehicle (CDDP/gel) which consisted of purified 
bovine collagen (a protein carrier), cisplatin and a vaso-constrictor, epinephrine (Deurloo et 
al., 1991). The therapeutic implant provides sustained release of drug in tumors and greatly 
reduces systemic toxicity (Krag et al., 1990). Recent studies with human SCCA transplant 
models combining intratumor chemotherapy with LITT encourages further development of 
this novel combined therapy to successfully eradicate marginal disease for treatment of 
recurrent head and neck cancer (Chung et al., 2003). 
 The rationale for combined treatment is that during LITT, high photo thermal laser energy 
levels are delivered to the area of maximum obstruction in the tumor core, inducing 
irreversible coagulative changes and lower levels at the tumor margin. Less energy is 
delivered to the margins because of higher risk of organ perforation or damage to 
neighboring tissues (Paiva et al., 1997). LITT debulking procedures causes boiling of tissue 
water and subsequent irreversible thermal damage, which will ultimately lead to photo-
evaporation at the tumor core (100 oC) (Chapman, 1998; Hallddorsson and Langerholc, 
1978; Marchesini et al., 1985; Morrison et al., 1998). Local recurrence after LITT is related to 
residual disease due to reversible cellular thermal damage on the margins treated with 
subtherapeutic energy levels (40-60oC) in head and neck and prostate tumor ablation (Anzai 
et al., 1991; Marchesini et al., 1985). Toxicity enhancement of cisplatin at these temperatures 
(40-60oC) would promote optimal eradication of cancer cells at the tumor margins. Under 
such rationale, enhanced laser therapy by adjuvant local chemotherapy using CDDP/gel in 
the region of subtherapeutic energy levels was first demonstrated in an experimental model 
by Paiva et al. (1997).  
Using authographic imaging method, Kanekal et al. (1995) tested cisplatin radiotracer in 
suspension (195mPt-CDDP, 4mg/ml) and gel implant form (195mPt-CDDP/gel, 4mg/ml) to 
compare tumor retention in 600mm3 subcutaneous tumors in experimental murine model. 
Intratumor CDDP/gel provided a uniform drug concentration at the margins of the tumor 
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at 4 hours, and 80% drug retention in the tumor as opposed to rapid systemic washout of 
195mPt-CDDP in suspension after intratumor administration. Higher intratumor CDDP levels 
can allow enhanced direct toxicity as well as a synergistic interaction with laser 
hyperthermia to further promote cisplatin cytotoxicity (Begg et al., 1994; Graeber et al., 1999; 
Theon et al., 1994). This hypothesis was tested in multiple studies in which intra-tumor 
CDDP/gel injections were combined with LITT for enhanced therapy in the tumor margins 
and further improvement in cancer treatment. This body of translational work provided the 
groundwork for clinical application of CDDP/gel and LITT for recurrent head and neck 
cancer (Paiva et al., 2005b). The CDDP/gel dose was based in phase II-III studies where 2.0 
mg CDDP/cm3 tumor was determined to be tolerable, contributed to tumor responses, and 
provided volume dosing to adequately infiltrate tumor masses. Using this vehicle, 1 mL of 
CDDP/gel delivers 2 mg of CDDP (Burris et al., 1998; Castro et al., 2003). In one study, eight 
patients were treated using the CDDP/gel implant and laser combination (oral n=1; neck 
n=3; skin n=2; maxillary sinus n=1; breast n=1) where the end point was to study drug 
toxicity (Bublik et al., 2010). None of the patients experienced toxicity at the levels of laser 
(2,200J/cm2) and drug (2mg/CDDP per cm3 of tumor) tested. However, additional studies 
are needed to guarantee the safety of combining both treatment modalities. Other studies 
have confirmed that intratumor injection of cisplatin at 2mg/ml is safe in well-established 
clinical protocols exploring electro-chemo-poration treatment for skin cancer (Sersa et al., 
2000a; Sersa et al., 2000b).  
A more recent study by Kanekal et al. (2009) showed that intratumor injections of CDDP in 
solution washed out after 5 minutes, which shows that combined treatment with LITT could 
be performed as a one-step procedure in the operating room. This would obviate the need 
for waiting between tumor injection and laser treatment (typically 4 to 48 hours), making the 
treatment protocol more efficient and streamlined for patients. Probably the most relevant 
clinical investigation testing intratumor injection of chemotherapy combined with laser 
thermal therapy was published by Wang et al. (2001) who reported 100% complete 
responses in 33 patients with T1-2 esophageal squamous cell carcinoma. In this work 
intratumor injection of bleomycin was combined with LITT for esophageal tumors and 
followed for an average 29 months. The combined minimally invasive procedure proposed 
has a strong translational potential as a cost effective alternative treatment not only for head 
and neck but for other accessible inoperable primary and/or recurrent tumors of the chest 
wall, breast, liver, prostate and colon (Castro et al., 1994; Chapman, 1998; Mueller-Lisse et 
al., 1998; Paiva et al., 1998a; Schulze et al., 2002; Vogl et al., 2002a; Vogl et al., 1997; Stafford 
et al., 2010; Sercarz et al., 2010).  
7. Future development  
The next phase of the experimental model for intratumor injections of CDDP followed by 
LITT will be to introduce the concept of “vascular collapse” potentiating high dose 
chemotherapy and localized hyperthermia. Peralta et al. (2010) et al. recently described 
massive thermal injury to arteries and veins resulting in vascular collapse due to high 
energy density using the Nd:YAG laser powered at 30-45W for treatment of severe twin-
twin transfusion syndrome. This is the same energy level used by our group for head and 
neck thermal ablation (2,200-3,300 J/cm2) of cancer (Bublik et al., 2006; Sercarz et al., 2010). 
In theory, the peripheral vascular collapse of arteries and veins produced by LITT will 
isolate blood flow to and from the tumor, thereby impeding drug (CDDP) washout to the 
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rest of the body. Consequently, high cisplatin concentration in the tumor will potentiate the 
cytotoxic synergistic combination of drug and heat, and promote more effective treatment. 
Potentially, intratumor injections of cisplatin may be increased up to 40mg as recently 
reported by Celikoglu et al. (2006) in a clinical trial testing local chemotherapy (CDDP/sol) 
and radiation for inoperable bronchogenic tumor, where no adverse effects were observed. 
The vascular collapse will avoid systemic diffusion of cisplatin and allow us to attain a very 
high concentration of CPPD in the tumor margins as first suggested by Sakurai et al., in 
1996. High doses of CDDP/sol will significantly improve the combined treatment proposed 
(Kanekal et al., 2009). 
Further progress in laser chemotherapy may be an outgrowth of the current excitement 
surrounding nanoscience and the promise of new nanoscale applications in cancer 
diagnostics and therapy. Because of their strongly resonant light-absorbing and light-
scattering properties that depend on shape, noble metal nanoparticles provide a new and 
powerful tool for innovative light-based approaches. Nanoshells are spherical, dielectric 
core, gold shell nanoparticles that have been central to the development of photo thermal 
cancer therapy and diagnostics for the past several years. By manipulating nanoparticle 
shape, researchers can tune the optical resonance of nanoshells to any wavelength of interest 
(Lal et al., 2008). 
Nanoshells are optically tunable core/shell nanoparticles that can be fabricated to strongly 
absorb in the near-infrared (NIR) region where light transmits deeply into tissue. When 
injected systemically, these particles have been shown to accumulate within the tumor due 
to the enhanced permeability and retention effect and induce photo thermal ablation of the 
tumor when irradiated with an NIR laser. Tumor specificity can be increased via 
functionalizing the nanoshell surface with tumor-targeting moieties. Nanoshells can also be 
made to strongly scatter light and therefore can be used in various imaging modalities such 
as dark-field microscopy and optical coherence tomography - OCT (Morton et al., 2010).  
An interesting application of nanoshell research was demonstrated by Hirsch et al. (2006) by 
incubating human breast carcinoma cells with nanoshells in vitro. The breast carcinoma cells 
found to have undergone photo-thermally induced morbidity on exposure to NIR light (820 
nm) as determined by using a fluorescent viability stain. Cells without nanoshells displayed 
no loss in viability after the same periods and conditions of NIR illumination. Likewise, in 
vivo studies under magnetic resonance guidance revealed that exposure to low doses of NIR 
light in solid tumors treated with metal nanoshells reached average maximum temperatures 
capable of inducing irreversible tissue damage (ΔT = 37.4 ± 6.6°C) within 4-6 min. Controls 
treated without nanoshells demonstrated significantly lower average temperatures on 
exposure to NIR light (ΔT < 10°C). These results demonstrate a good correlation with the 
histological findings: tissues heated above the thermal damage threshold displayed 
coagulation, cell shrinkage, and loss of nuclear staining, which are all indicators of 
irreversible thermal damage, whereas control tissues appeared undamaged. Now that a 
regime of nanoshell and laser dosage has been established for successful therapy of 
nanoshell-treated tumors, survival studies monitoring tumor growth/regression of entire 
tumors after treatment with the NIR nanoshell therapy under MR guidance are possible.  
Future investigation of a targeted nanoshell therapy that is similar in many ways to the 
delivery of stealth liposomes is warranted. In this approach, nanoshells “stealthed” with 
PEG are systemically injected and preferentially accumulate at the tumor site due to the 
highly permeable, poorly organized vascular networks commonly found in tumors 
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(Papahadjopoulos et al., 1991; Wu et al., 1993). This preferential accumulation behavior is 
often referred to as the enhanced permeability and retention effect (Maeda, 2001). NIR 
treatment of the bulk tissue then selectively heats and destroys the nanoshell-laden tumor 
regions within the tissue, leaving surrounding tissue intact. As an additional adjuvant, 
nanoshells may also be conjugated with antibodies targeting surface oncoproteins 
overexpressed by tumor cells. These antibodies would enhance target specificity and cellular 
internalization resulting in more selective thermal damage to the tumor. Such therapies 
could have a large impact on the treatment of secondary metastases and other tumors 
considered to be otherwise inoperable (Lal et al., 2008). 
8. Conclusions 
Innovative approaches are being explored in many areas of medicine to reduce costs by 
increasing both efficiency and effectiveness of patient care. Less invasive surgical access has 
allowed more rapid recovery and decreased inpatient costs for procedures ranging from 
laparoscopic cholecystectomy to neurosurgery for cerebral neoplasms. Advanced electronic 
devices including color Doppler ultrasound, open magnetic resonance imaging, and low-
cost semiconductor laser fiber optics can be coupled for accurate detection and improved 
tumor ablation without open surgical access in many anatomic sites. Imaging guided 
interstitial laser therapy is minimally invasive and cab be repeated as an outpatient 
procedure for improved palliation of recurrent tumors. We and others have performed 
UTZ-guided or MRI-guided LITT during the last 18 years for unresectable and recurrent 
head and neck cancer.  
Because head and neck cancers are accessible for surgery and have a well described loco-
regional biological behavior, they are an ideal model to test combined laser energy delivered 
via interstitial fiber optics and chemotherapeutic agents activated by photo-thermal energy 
as an alternative, less invasive treatment for cancer. Long term remission and tumor 
eradication may be possible by combining intratumor chemotherapy with photo-thermal 
energy delivery via laser fiber optics. In this model, cisplatin and hyperthermia have been 
shown to an effective combined therapy in the laboratory and in recent clinical trials. In 
addition to therapeutic benefits and improved tumoricidal effects, combining intralesional 
anti-cancer drugs with interstitial photo-thermal laser treatment reduces systemic toxicity 
and is less invasive than conventional chemotherapy or surgical resection. This research will 
benefit from recent advances in development of low-cost imaging systems for real-time 
monitoring during minimally invasive procedures. Photo-chemotherapy promises to 
become a useful adjunctive modality for tumor palliation in advanced cancer patients and 
may represent one of many future biomedical applications of quantum microeletronics 
devices and nonothechnology in surgical oncology.  
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